![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: UBE2S |
Gene summary for UBE2S |
![]() |
Gene information | Species | Human | Gene symbol | UBE2S | Gene ID | 27338 |
Gene name | ubiquitin conjugating enzyme E2 S | |
Gene Alias | E2-EPF | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q16763 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27338 | UBE2S | CA_HPV_1 | Human | Cervix | CC | 1.04e-02 | -1.85e-01 | 0.0264 |
27338 | UBE2S | CA_HPV_2 | Human | Cervix | CC | 3.55e-02 | 3.02e-01 | 0.0391 |
27338 | UBE2S | CA_HPV_3 | Human | Cervix | CC | 1.25e-05 | 9.61e-02 | 0.0414 |
27338 | UBE2S | N_HPV_2 | Human | Cervix | N_HPV | 7.40e-04 | 1.41e-01 | -0.0131 |
27338 | UBE2S | CCI_1 | Human | Cervix | CC | 4.94e-03 | -5.07e-01 | 0.528 |
27338 | UBE2S | CCI_3 | Human | Cervix | CC | 3.66e-02 | -4.21e-01 | 0.516 |
27338 | UBE2S | CCII_1 | Human | Cervix | CC | 1.85e-08 | -5.16e-01 | 0.3249 |
27338 | UBE2S | LZE2T | Human | Esophagus | ESCC | 8.89e-07 | 1.27e+00 | 0.082 |
27338 | UBE2S | LZE4T | Human | Esophagus | ESCC | 6.44e-17 | 5.94e-01 | 0.0811 |
27338 | UBE2S | LZE7T | Human | Esophagus | ESCC | 2.34e-04 | 3.96e-01 | 0.0667 |
27338 | UBE2S | LZE20T | Human | Esophagus | ESCC | 4.15e-11 | 6.16e-01 | 0.0662 |
27338 | UBE2S | LZE22D1 | Human | Esophagus | HGIN | 4.16e-02 | 1.72e-01 | 0.0595 |
27338 | UBE2S | LZE22T | Human | Esophagus | ESCC | 1.65e-07 | 8.28e-01 | 0.068 |
27338 | UBE2S | LZE24T | Human | Esophagus | ESCC | 1.38e-23 | 9.69e-01 | 0.0596 |
27338 | UBE2S | LZE21T | Human | Esophagus | ESCC | 1.84e-10 | 1.14e+00 | 0.0655 |
27338 | UBE2S | P1T-E | Human | Esophagus | ESCC | 3.20e-19 | 7.48e-01 | 0.0875 |
27338 | UBE2S | P2T-E | Human | Esophagus | ESCC | 1.72e-34 | 9.65e-01 | 0.1177 |
27338 | UBE2S | P4T-E | Human | Esophagus | ESCC | 1.36e-65 | 1.92e+00 | 0.1323 |
27338 | UBE2S | P5T-E | Human | Esophagus | ESCC | 3.63e-52 | 1.19e+00 | 0.1327 |
27338 | UBE2S | P8T-E | Human | Esophagus | ESCC | 5.34e-36 | 9.92e-01 | 0.0889 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
GO:00002097 | Cervix | CC | protein polyubiquitination | 58/2311 | 236/18723 | 1.57e-07 | 7.41e-06 | 58 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:19046669 | Cervix | CC | regulation of ubiquitin protein ligase activity | 12/2311 | 23/18723 | 4.41e-06 | 1.12e-04 | 12 |
GO:00514387 | Cervix | CC | regulation of ubiquitin-protein transferase activity | 18/2311 | 53/18723 | 3.69e-05 | 5.84e-04 | 18 |
GO:00313983 | Cervix | CC | positive regulation of protein ubiquitination | 25/2311 | 119/18723 | 5.09e-03 | 3.01e-02 | 25 |
GO:19033224 | Cervix | CC | positive regulation of protein modification by small protein conjugation or removal | 28/2311 | 138/18723 | 5.26e-03 | 3.08e-02 | 28 |
GO:00705343 | Cervix | CC | protein K63-linked ubiquitination | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
GO:01400143 | Cervix | CC | mitotic nuclear division | 50/2311 | 287/18723 | 7.27e-03 | 3.91e-02 | 50 |
GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
GO:003139625 | Cervix | N_HPV | regulation of protein ubiquitination | 24/534 | 210/18723 | 8.06e-09 | 1.60e-06 | 24 |
GO:190332025 | Cervix | N_HPV | regulation of protein modification by small protein conjugation or removal | 25/534 | 242/18723 | 3.05e-08 | 3.66e-06 | 25 |
GO:190466625 | Cervix | N_HPV | regulation of ubiquitin protein ligase activity | 5/534 | 23/18723 | 4.07e-04 | 5.77e-03 | 5 |
GO:005143824 | Cervix | N_HPV | regulation of ubiquitin-protein transferase activity | 7/534 | 53/18723 | 7.30e-04 | 9.21e-03 | 7 |
GO:001049815 | Cervix | N_HPV | proteasomal protein catabolic process | 27/534 | 490/18723 | 9.06e-04 | 1.08e-02 | 27 |
GO:005125824 | Cervix | N_HPV | protein polymerization | 19/534 | 297/18723 | 9.32e-04 | 1.11e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0412012 | Lung | IAC | Ubiquitin mediated proteolysis | 40/1053 | 142/8465 | 3.24e-07 | 1.76e-05 | 1.17e-05 | 40 |
hsa0412013 | Lung | IAC | Ubiquitin mediated proteolysis | 40/1053 | 142/8465 | 3.24e-07 | 1.76e-05 | 1.17e-05 | 40 |
hsa0412020 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa04120110 | Oral cavity | OSCC | Ubiquitin mediated proteolysis | 105/3704 | 142/8465 | 1.83e-13 | 4.37e-12 | 2.23e-12 | 105 |
hsa0412025 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
hsa0412035 | Oral cavity | LP | Ubiquitin mediated proteolysis | 66/2418 | 142/8465 | 3.74e-06 | 3.46e-05 | 2.23e-05 | 66 |
hsa0412061 | Oral cavity | NEOLP | Ubiquitin mediated proteolysis | 43/1112 | 142/8465 | 5.78e-08 | 9.19e-07 | 5.78e-07 | 43 |
hsa0412071 | Oral cavity | NEOLP | Ubiquitin mediated proteolysis | 43/1112 | 142/8465 | 5.78e-08 | 9.19e-07 | 5.78e-07 | 43 |
hsa0412018 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0412019 | Prostate | BPH | Ubiquitin mediated proteolysis | 61/1718 | 142/8465 | 5.50e-10 | 9.07e-09 | 5.61e-09 | 61 |
hsa0412024 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
hsa0412034 | Prostate | Tumor | Ubiquitin mediated proteolysis | 61/1791 | 142/8465 | 3.08e-09 | 5.09e-08 | 3.16e-08 | 61 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UBE2S | SNV | Missense_Mutation | novel | c.260N>G | p.Asn87Ser | p.N87S | Q16763 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
UBE2S | SNV | Missense_Mutation | rs780497000 | c.653C>T | p.Ala218Val | p.A218V | Q16763 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
UBE2S | SNV | Missense_Mutation | novel | c.403C>T | p.Arg135Cys | p.R135C | Q16763 | protein_coding | deleterious(0.05) | probably_damaging(0.974) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
UBE2S | SNV | Missense_Mutation | novel | c.18N>T | p.Glu6Asp | p.E6D | Q16763 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
UBE2S | SNV | Missense_Mutation | novel | c.652N>A | p.Ala218Thr | p.A218T | Q16763 | protein_coding | tolerated(0.32) | probably_damaging(0.977) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
UBE2S | SNV | Missense_Mutation | novel | c.403N>T | p.Arg135Cys | p.R135C | Q16763 | protein_coding | deleterious(0.05) | probably_damaging(0.974) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UBE2S | SNV | Missense_Mutation | rs374069290 | c.40N>T | p.Arg14Cys | p.R14C | Q16763 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-FV-A3I0-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
UBE2S | SNV | Missense_Mutation | c.578G>A | p.Gly193Asp | p.G193D | Q16763 | protein_coding | deleterious(0.02) | probably_damaging(0.984) | TCGA-55-6985-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
UBE2S | SNV | Missense_Mutation | c.37N>T | p.Ile13Phe | p.I13F | Q16763 | protein_coding | deleterious(0) | benign(0.28) | TCGA-69-7765-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD | |
UBE2S | SNV | Missense_Mutation | novel | c.262N>T | p.Val88Leu | p.V88L | Q16763 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-CR-7372-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |